Ikonisys SA announced that Hospitex has signed a new distribution partnership in Ukraine with Diagen LLC. This collaboration aims at reinforcing the Company's commitment to the global fight against cancer. Despite the challenging environment amidst the war, this strategic alliance represents a significant step in Hospitex's mission to enhance the accessibility of advanced cancer diagnostic tools and treatments and make innovative healthcare solutions available to those who need them most.

The market for cytology in Ukraine is substantial with a growing emphasis on early cancer detection and preventive healthcare. Urinary cytology is also becoming more significant, with thousands of tests performed each year to diagnose and monitor urinary tract cancers. By introducing Hospitex's advanced diagnostic products into this market, the aim is to significantly enhance the accuracy and efficiency of critical tests.

In the framework of this partnership, Diagen LLC will both distribute Hospitex's cutting-edge technologies and use them in its own laboratory, particularly for Pap smear tests and urinary cytology. Thanks to Hospitex's expertise, Diagen LLC will enable Ukrainian healthcare professionals to have access to reliable and precise diagnostic tools. The first delivery to Diagen LLC has recently been recorded contributing to H1 2024 Hospitex's revenue.

The next phase of this collaboration consists into introducing Ikonisys' products into the Ukrainian market, further enhancing diagnostic capabilities and patient care. This collaboration is part of Hospitex's and Ikonisys' broader strategy to expand their global footprint and provide essential medical technology to underserved regions. By enhancing their distribution network, the Companies are taking proactive steps to address the global burden of cancer, delivering hope and improved health outcomes to communities in need.